Developmental and Epileptic Encephalopathy 77 (DEE77): A Comprehensive Disease Characterization

Disease: Developmental and Epileptic Encephalopathy 77 (DEE77) MONDO ID: MONDO:0032808 · OMIM: #618548 · Causal gene: PIGQ (16p13.3) Category: Mendelian (autosomal recessive inherited GPI-anchor deficiency)

Summary

Developmental and Epileptic Encephalopathy 77 (DEE77; also indexed as Early Infantile Epileptic Encephalopathy 77 / EIEE77 and as Multiple Congenital Anomalies–Hypotonia–Seizures syndrome 4 / MCAHS4) is an ultra-rare autosomal-recessive disorder caused by biallelic loss-of-function / hypomorphic variants in PIGQ (phosphatidylinositol glycan anchor biosynthesis class Q; HGNC:14135; formerly GPI1), located on chromosome 16p13.3. PIGQ is a subunit of the GPI-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the very first, committed step of glycosylphosphatidylinositol (GPI) anchor biosynthesis on the cytoplasmic face of the endoplasmic reticulum. Because GPI anchoring tethers >150 diverse cell-surface proteins (enzymes, adhesion molecules, receptors, complement regulators), PIGQ deficiency produces a systemic inherited GPI deficiency (IGD) with a neurodevelopmental core.

The disease was first recognized in 2014, when whole-genome sequencing of severe early-onset epilepsy trios identified a recessive PIGQ splice/exon-skipping variant in an Ohtahara-syndrome patient (PMID: 24463883). The definitive phenotypic delineation came from Johnstone et al. 2020, who reported seven new biallelic-PIGQ subjects with functional confirmation (PMID: 32588908). Clinically, DEE77 presents in early infancy (seizure onset ~2.5–7 months) with drug-resistant epileptic seizures, axial hypotonia, global developmental delay/intellectual disability, progressive cerebral and cerebellar atrophy, and multisystem (gastrointestinal and cardiac) anomalies. Premature death occurs in more than half of reported patients. A milder end of the spectrum — nonprogressive congenital ataxia with intellectual disability and generalized epilepsy — has also been described (PMID: 34089469).

There is no disease-modifying therapy. Management is supportive and symptomatic, with anti-seizure medications; high-dose vitamin B6 (pyridoxine / pyridoxal-5′-phosphate) provides partial seizure benefit in a subset of IGD patients but rarely achieves seizure freedom. Diagnosis rests on exome/genome sequencing confirmed functionally by flow cytometry showing reduced surface GPI-anchored proteins (e.g., FLAER, CD16, CD14) on granulocytes/leukocytes. Prevention relies on genetic counseling with prenatal / preimplantation genetic testing for at-risk (often consanguineous) families. This report synthesizes nine confirmed findings across the full disease-characterization template.

1. Disease Information

Overview. DEE77 is a monogenic, autosomal-recessive developmental and epileptic encephalopathy belonging to the family of inherited glycosylphosphatidylinositol (GPI) deficiencies (IGDs) — congenital disorders of glycosylation affecting the biosynthesis or remodeling of the GPI anchor. It is characterized by early-infantile-onset epilepsy that is frequently drug-resistant, together with severe global developmental impairment and congenital multisystem anomalies.

Key identifiers (cross-references verified via OLS for MONDO:0032808):

Synonyms / alternative names: Developmental and epileptic encephalopathy 77; DEE77; Early infantile epileptic encephalopathy 77; EIEE77; PIGQ-related GPI deficiency; Multiple congenital anomalies–hypotonia–seizures syndrome 4 (MCAHS4).

Information source type. Knowledge is derived almost entirely from aggregated disease-level resources (OMIM, MONDO, ClinVar) and from small published case series / individual case reports (Martin 2014; Johnstone 2020; Zanni 2022), not from large EHR-based cohorts. The largest quantitative context comes from a pooled IGD cohort (Sidpra et al. 2024; n=83) that includes PIGQ among other GPI-pathway genes (PMID: 38456468).

2. Etiology

Primary cause — genetic. DEE77 is caused by biallelic (autosomal recessive) pathogenic variants in PIGQ. There is no environmental, infectious, or acquired etiology; the disorder is fully Mendelian. The first causal link was reported by Martin et al. 2014, who identified a recessive PIGQ mutation causing exon skipping and defective GPI biosynthesis in an Ohtahara-syndrome patient among six whole-genome-sequenced severe early-onset epilepsy trios:

"The fourth OS patient had a recessive mutation in PIGQ that led to exon skipping and defective glycophosphatidyl inositol biosynthesis." — PMID: 24463883

Johnstone et al. 2020 then confirmed and expanded the etiology with seven new biallelic-PIGQ subjects from six families:

"We investigated seven children from six families to expand the phenotypic spectrum associated with an early infantile epileptic encephalopathy caused by biallelic pathogenic variants in the phosphatidylinositol glycan anchor biosynthesis class Q (PIGQ) gene." — PMID: 32588908

Genetic risk factors. The causal factor is the biallelic PIGQ genotype itself. Consanguinity is an important risk factor (homozygous variants recur in consanguineous families, e.g., the homozygous c.1631dupA reported by Zanni et al. 2022). Compound heterozygosity accounts for cases in non-consanguineous families. No modifier genes have been formally established for DEE77, although residual enzymatic activity of hypomorphic alleles is the principal determinant of severity (see §4, §9).

Environmental risk / protective factors and gene–environment interactions. None are established. As a purely Mendelian recessive disorder, environmental exposures do not cause DEE77. The only clinically actionable "environmental" modifier is nutritional/pharmacological — vitamin B6 (pyridoxine) partially mitigates seizures in a subset of IGD patients (see §12), representing a gene–treatment rather than a gene–environment interaction. No protective alleles are known.

3. Phenotypes

The DEE77 phenotype is dominated by a neurodevelopmental triad (epilepsy + hypotonia + developmental delay) with frequent multisystem congenital anomalies. Frequencies below combine the PIGQ-specific series (Johnstone 2020, n=7; Zanni 2022) with the pooled IGD cohort (Sidpra 2024, n=83) where PIGQ-specific numbers are unavailable.

Key supporting quotes:

"Epileptic seizures, axial hypotonia, developmental delay and multiple congenital anomalies were consistently observed. Seizure onset occurred between 2.5 months and 7 months of age and varied from treatable seizures to recurrent episodes of status epilepticus." — PMID: 32588908

"Core clinical features were developmental delay or intellectual disability (DD/ID, 90%), seizures (83%), hypotonia (72%) and motor symptoms (64%)." — PMID: 38456468

Progression and severity. The severe end shows progressive neurodegeneration (progressive atrophy, hypomyelination) and high early mortality; a milder, nonprogressive end (congenital ataxia with ID and generalized epilepsy, cerebellar atrophy) is documented (PMID: 34089469). Severity correlates with residual PIGQ/GPI-biosynthetic activity.

Quality-of-life impact. Not formally measured with EQ-5D/SF-36/PROMIS in this ultra-rare disorder. Qualitatively, the impact is profound: affected children have severe cognitive/motor disability, drug-resistant seizures, feeding difficulties, and dependence on full-time caregiving; many do not survive early childhood.

4. Genetic / Molecular Information

Causal gene — PIGQ.

Pathogenic variant spectrum (ClinVar, 300 records queried).

By molecular type across the record set: 268 SNVs, 17 deletions, 7 duplications, 2 microsatellite, plus rare CNV gains/losses and 1 inversion. DEE77 variants are predominantly small-scale (missense, nonsense, frameshift, splice-site), with occasional copy-number/structural events. Representative variants: the exon-skipping splice variant of Martin 2014 (PMID: 24463883) and the homozygous frameshift NM_004204.5:c.1631dupA (p.Tyr544fs*79) of Zanni 2022 (PMID: 34089469).

Population constraint (gnomAD, computed). PIGQ is heterozygous LoF-tolerant, consistent with a recessive mechanism: gnomAD v2 pLI ≈ 0 (5.7e-17), LOEUF (oe_lof upper) = 1.12, observed/expected LoF = 0.90 (54 obs vs 60.3 exp), missense Z = −0.08. Heterozygous carriers are unaffected — concordant with the historical observation that heterozygous 16p13.3 deletions removing one GPI1 allele (in α-thalassemia/mental retardation) do not overtly impair GPI-anchored protein expression (PMID: 11418246).

Functional consequence. Loss of function / hypomorphic. Complete null is presumed embryonic-lethal; viable patients retain residual GPI-biosynthetic activity. Functional proof of causality: transfection of wild-type PIGQ cDNA into patient fibroblasts rescued the GPI-anchored-protein deficiency (see §6).

Modifier genes / epigenetics / large chromosomal abnormalities. No DEE77-specific modifier genes or epigenetic mechanisms are established. Whole-gene deletions or 16p13.3 CNVs are rare contributors; most disease arises from small biallelic variants.

5. Environmental Information

Not applicable. DEE77 is a monogenic recessive disorder with no environmental, lifestyle, toxic, radiation, occupational, or infectious cause or trigger. No dietary, behavioral, or exposure-based risk or protective factors have been identified. The only exogenous factor with clinical relevance is therapeutic vitamin B6 (pyridoxine/pyridoxal-5′-phosphate), which partially reduces seizures in some IGD patients (see §12) — a treatment effect, not a disease cause.

6. Mechanism / Pathophysiology

Ordered causal chain

1. Biallelic hypomorphic/LoF PIGQ variants reduce functional PIGQ protein → leads to
2. Impaired GPI-N-acetylglucosaminyltransferase (GPI-GnT) complex on the cytoplasmic face of the ER, of which PIGQ is a subunit → results in
3. Failure of the first committed step of GPI biosynthesis (transfer of GlcNAc onto phosphatidylinositol) → leads to
4. Global reduction in GPI anchor synthesis → results in
5. Reduced cell-surface expression of >150 GPI-anchored proteins (enzymes, adhesion molecules, receptors, complement regulators) — directly demonstrated in patient granulocytes and fibroblasts → leads to (branch point)
6. 5a. Neuronal branch: loss of GPI-anchored proteins critical to neuronal development, synapse formation, and cortical excitability → results in → epileptogenesis, hypotonia, developmental delay, progressive cerebral/cerebellar atrophy (inferred from human phenotype + mouse GPI-deficiency models).
7. 5b. Systemic/developmental branch: loss of GPI-anchored proteins in non-neural tissues during organogenesis → results in → gastrointestinal (volvulus), cardiac, renal congenital anomalies.
8. Combined CNS and multisystem dysfunction → results in → early-infantile DEE77 with high mortality.

Molecular and cellular detail

PIGQ's molecular role is defined precisely:

"PIGQ encodes the phosphatidylinositol glycan class Q protein and is part of the GPI-N-acetylglucosaminyltransferase complex that initiates GPI biosynthesis from phosphatidylinositol (PI) and N-acetylglucosamine (GlcNAc) on the cytoplasmic side of the endoplasmic reticulum (ER)." — PMID: 34089469

The GPI-GnT ring complex also includes ARV1, which recruits phosphatidylinositol and associates directly with PIGQ:

"ARV1 associates with PIGQ, a GPI-GnT component" — PMID: 40378954

Direct functional proof in human cells (loss of GPI-anchored proteins is the proximate mechanism, and it is PIGQ-specific):

"Flow cytometry using granulocytes and fibroblasts from affected individuals showed reduced expression of glycosylphosphatidylinositol (GPI)-anchored proteins. Transfection of wildtype PIGQ cDNA into patient fibroblasts rescued this phenotype." — PMID: 32588908

Upstream vs downstream. The PIGQ mutation and GPI-GnT dysfunction are upstream; loss of specific GPI-anchored proteins (e.g., complement regulators, folate receptor-α, alkaline phosphatase-related processing, neural adhesion molecules) and the resulting neuronal/organ dysfunction are downstream.

Cellular processes and compartments. The initiating lesion is in the endoplasmic reticulum (GO:0005789, ER membrane; cytoplasmic face). Affected biological processes: GPI anchor biosynthetic process (GO:0006506), GPI anchor metabolic process (GO:0006505), protein lipidation / attachment of GPI anchor to protein (GO:0016255). Downstream neural processes include regulation of neuron differentiation and regulation of synaptic transmission / neuronal excitability.

Biochemical hallmark shared across IGD. Some IGD subtypes show hyperphosphatasia (elevated serum alkaline phosphatase, itself a GPI-anchored enzyme aberrantly shed when anchoring fails); this is variable in PIGQ disease. Folate receptor-α (FOLR1) is a GPI-anchored protein, providing a mechanistic rationale for cerebral folate involvement and folinic-acid relevance (PMID: 19732866).

Cell types (CL suggestions): neuron (CL:0000540), GABAergic/inhibitory neuron (CL:0000617), glutamatergic/excitatory neuron (CL:0000679), granulocyte/neutrophil (CL:0000775 — diagnostic readout), fibroblast (CL:0000057 — diagnostic readout).

7. Anatomical Structures Affected

Organ level — primary. The brain / central nervous system (UBERON:0000955, brain; UBERON:0001017, CNS) is the primary affected organ. Within the brain, the cerebral cortex (UBERON:0000956), cerebellum (UBERON:0002037), corpus callosum (UBERON:0002336), and white-matter tracts (hypomyelination; symmetric restricted diffusion of the central tegmental tracts, 60% in IGD pooled) are involved.

Secondary / multisystem involvement: - Gastrointestinal tract (UBERON:0001555) — anomalies in 66%, including life-threatening midgut volvulus. - Heart (UBERON:0000948) — structural anomalies and arrhythmias in ~19%. - Kidney (UBERON:0002113) — malformation in ~14%.

Body systems: nervous (primary), digestive, cardiovascular, and renal/urinary (secondary).

Tissue and cell level. Primarily nervous tissue (excitatory and inhibitory cortical neurons, cerebellar neurons). Because GPI anchoring is ubiquitous, epithelial and other tissues are affected during organogenesis. Diagnostic readouts use hematopoietic cells (granulocytes/leukocytes) and fibroblasts.

Subcellular level. The initiating defect is at the endoplasmic reticulum membrane, cytoplasmic face (GO:0005789). The functional deficit manifests at the plasma membrane (GO:0005886) as loss of GPI-anchored surface proteins, i.e., in the anchored component of the plasma membrane (GO:0031225).

Localization / lateralization. CNS involvement is bilateral and largely symmetric (symmetric atrophy, symmetric restricted diffusion of central tegmental tracts).

8. Temporal Development

Onset. Early-infantile / congenital. Congenital hypotonia and multiple congenital anomalies are present at/near birth; seizure onset occurs between 2.5 and 7 months (PMID: 32588908). Median age at seizure onset across the IGD family is ~6 months (PMID: 38456468). Onset pattern is chronic with early emergence, punctuated by acute events (status epilepticus, volvulus).

Progression. At the severe end the course is progressive: recurrent/refractory seizures, progressive cerebral and cerebellar atrophy, and hypomyelination, with declining function. At the mild end (Zanni 2022) the course is nonprogressive congenital ataxia. Disease is lifelong (chronic) when survived.

Patterns. Seizures range from treatable to recurrent status epilepticus; no reliable spontaneous remission is documented. Critical period: the fetal/early-infantile window of neurodevelopment is the period of vulnerability; because the disease "progresses even after birth," early diagnosis and initiation of supportive/pyridoxine therapy is advocated as a potential window of opportunity (PMID: 26165085).

9. Inheritance and Population

Epidemiology. DEE77 is ultra-rare: only ~15–20 patients reported worldwide since 2014 (Martin 2014 first case; Johnstone 2020 +7; Zanni 2022 +1; scattered others). The case count is too small for formal prevalence/incidence estimates, and no Orphanet point-prevalence figure is available.

"Pathogenic variants in the PIGQ gene have been previously reported in 10 patients with congenital hypotonia, early-infantile epileptic encephalopathy, and premature death occurring in more than half cases." — PMID: 34089469

Inheritance. Autosomal recessive, biallelic PIGQ — homozygous (often consanguineous) or compound heterozygous.

"The fourth OS patient had a recessive mutation in PIGQ" — PMID: 24463883

Carrier / birth-frequency estimate (gnomAD v4, computed). Summed high-confidence pLoF allele frequency q ≈ 1.75e-3 → naïve Hardy–Weinberg carrier frequency ≈ 2q ≈ 1/286, and biallelic-LoF birth frequency q² ≈ 1/327,600. This markedly overestimates true disease incidence because complete PIGQ null is presumed embryonic-lethal, and viable patients require at least one hypomorphic (residual-activity) allele; the true birth prevalence is far lower and unquantified.

Penetrance / expressivity. Penetrance of biallelic pathogenic genotypes appears complete; expressivity is variable — from lethal early-infantile encephalopathy at the severe end to nonprogressive congenital ataxia at the mild end, tracking residual enzyme activity.

Other genetic features. No genetic anticipation (not a repeat-expansion disorder). No established founder variant. Consanguinity increases risk of homozygosity. No sex predilection (autosomal); reported cases include both sexes.

10. Diagnostics

Genetic testing (primary/definitive). DEE77 is diagnosed by exome (WES) or genome (WGS) sequencing, or by targeted GPI-biosynthesis / epileptic-encephalopathy gene panels that include PIGQ. Because PIGQ is intron-heavy, ES/WGS or panel capture is preferred over single-gene Sanger. Chromosomal microarray can detect rare 16p13.3 CNVs but is low-yield for the typical small biallelic variants. Reference transcript for variant reporting: NM_004204.5.

Functional confirmation. Flow cytometry demonstrating reduced surface GPI-anchored proteins on granulocytes/leukocytes and fibroblasts confirms pathogenicity and functional impact:

"Flow cytometry confirmed deficiency of several GPI-anchored proteins on leukocytes (CD14, FLAER)." — PMID: 34089469

FLAER (fluorescent aerolysin, which binds GPI anchors directly), CD16, CD14, and CD59/CD55 are standard markers.

Laboratory / biomarkers. Serum alkaline phosphatase may be elevated (hyperphosphatasia) in some IGD subtypes (variable in PIGQ). No specific circulating biomarker is validated for PIGQ-DEE77.

Neuroimaging (diagnostic/prognostic). Brain MRI is central:

"Prognostic and biologically significant neuroimaging features included cerebral atrophy (75%), cerebellar atrophy (60%), callosal anomalies (57%) and symmetric restricted diffusion of the central tegmental tracts (60%)." — PMID: 38456468

Electrophysiology. EEG documents the epileptic encephalopathy (slow background; multifocal/continuous epileptiform activity; patterns including epilepsy of infancy with migrating focal seizures and myoclonic status).

Clinical criteria / differential diagnosis. No disease-specific criteria beyond genotype + GPI-flow-cytometry. Differential diagnosis includes other inherited GPI deficiencies (PIGA, PIGT, PIGV, PIGO, PIGS, PIGW, etc.), other early-infantile DEEs, congenital disorders of glycosylation, and pyridoxine-dependent epilepsies (ALDH7A1) — distinguished by gene-specific sequencing and GPI-anchored-protein assays.

Screening. No population newborn screening exists. Cascade carrier testing of relatives and prenatal/preimplantation testing are available once the familial biallelic variants are known.

11. Outcome / Prognosis

Mortality. Prognosis is poor at the severe end: premature death occurs in >50% of reported PIGQ patients (PMID: 34089469), and biallelic PIGQ variants were explicitly associated with increased mortality:

"Pathogenic biallelic PIGQ variants were associated with increased mortality." — PMID: 32588908

In the pooled IGD cohort, 15/83 were deceased (PMID: 38456468). Deaths are typically from neurologic complications, status epilepticus, or surgical/systemic complications (e.g., midgut volvulus).

Morbidity / function. Survivors have severe, lifelong disability: profound developmental delay/intellectual disability, drug-resistant epilepsy, motor impairment (hypotonia, ataxia, dyskinesia), feeding difficulties, and sensory involvement (vision/hearing) in some. No validated QoL instruments have been applied.

Recovery potential. Limited. No disease-modifying therapy exists; the milder (nonprogressive) subgroup has a more stable but still impaired course.

Prognostic factors. Residual GPI-biosynthetic activity / variant severity is the principal prognostic determinant (severe LoF → early lethality; hypomorphic → milder ataxia). Neuroimaging features (cerebral/cerebellar atrophy, callosal anomalies, central-tegmental-tract diffusion restriction) are prognostically significant. Neonatal onset and refractory seizures portend worse outcome.

12. Treatment

Overview. There is no cure and no disease-modifying therapy for DEE77; management is supportive and symptomatic (anti-seizure medications, nutritional/feeding support, surgical correction of anomalies such as volvulus, developmental therapies). Epilepsy is frequently drug-resistant.

Vitamin B6 (pyridoxine / pyridoxal-5′-phosphate; NCIT: Pyridoxine, C939). A rational adjunct across IGD. A prospective compassionate-use cohort (Bayat et al. 2022; n=7 IGD, PIGA/PIGT/PIGV) using pyridoxine 20–30 mg/kg/day then P5P found partial benefit:

"We observed more than 50% seizure frequency reduction in 2 out of 7 and less than 50% reduction in another 3 out of 7 participants. No participants reached seizure freedom." — PMID: 35080266

"Early diagnosis and treatment are desirable because the disease progresses even after birth and vitamin B6(pyridoxine) is very effective for some patients with intractable seizures." — PMID: 26165085

Proof-of-concept targeted therapy (different GPI gene). Restoring GPI-anchored protein expression can control IGD seizures — an HDAC inhibitor (butyrate) increased PIGM transcription and surface GPI expression:

"the drug caused complete cessation of intractable seizures in a child with inherited GPI deficiency." — PMID: 17442906

This is a mechanism-anchored strategy but has not been tested in PIGQ-DEE77.

Folinic acid. Mechanistically relevant because folate receptor-α (FOLR1) is itself a GPI-anchored protein; cerebral folate deficiency is treatable with folinic acid (PMID: 19732866). Empirical benefit in PIGQ-DEE77 is unproven.

Advanced / experimental therapeutics. No gene therapy, cell therapy, RNA-based therapy, or PIGQ-targeted small molecule exists or is in trials. Highly purified cannabidiol has shown benefit in monogenic epilepsies broadly (PMID: 40126049) but is not PIGQ-specific.

Suggested NCIT clinical-intervention terms: Pyridoxine (C939), Pyridoxal Phosphate (C61970), Anticonvulsant Agent (C264), Folinic Acid/Leucovorin (C576), Supportive Care (C15272).

13. Prevention

Primary prevention. There is no way to prevent the biallelic genotype; primary prevention is reproductive — genetic counseling for at-risk families (especially consanguineous couples) with carrier testing, prenatal diagnosis, and preimplantation genetic testing (PGT-M) once familial PIGQ variants are known.

Secondary prevention. Cascade genetic testing of relatives; early molecular diagnosis to enable prompt supportive care and a trial of pyridoxine/P5P (rationale: the disease progresses postnatally, so early intervention is advocated — PMID: 26165085).

Tertiary prevention. Prevent complications: aggressive seizure management, surveillance and surgical correction of GI anomalies (volvulus), cardiac monitoring for arrhythmias, nutritional support, and developmental/rehabilitative therapies.

Immunization / public-health / environmental interventions. Not applicable (non-infectious, non-environmental Mendelian disorder). Standard childhood immunization for general health.

14. Other Species / Natural Disease

Taxonomy. No naturally occurring PIGQ-DEE77 has been described in companion animals or wildlife (no OMIA entry identified). GPI anchoring is universally essential across eukaryotes, so orthologs exist broadly. Human species: Homo sapiens (NCBI Taxon 9606); mouse: Mus musculus (NCBI Taxon 10090).

Orthologous genes. Mouse Pigq (ortholog of human PIGQ) exists; the pathway ortholog most studied for disease modeling is Piga (see §15).

Comparative biology. GPI-anchor biosynthesis is deeply evolutionarily conserved from yeast to humans; the essentiality of the pathway (embryonic lethality of complete knockout) is conserved, which is why disease modeling relies on conditional/tissue-specific approaches (§15).

Zoonotic / transmission. Not applicable — non-transmissible genetic disorder.

15. Model Organisms

No PIGQ-specific animal model has been published. Because complete GPI biosynthesis knockout is embryonic-lethal (GPI anchoring is essential for embryogenesis), disease modeling uses conditional / tissue-specific knockouts of pathway genes.

Key mouse model (Kandasamy et al. 2021). Neuron-type-specific GPI-deficiency mice were generated by conditional knockout of Piga — the gene catalyzing the same first, committed step of GPI biosynthesis in which PIGQ participates as a GPI-GnT subunit — in telencephalon excitatory neurons (Ex-M-cko), inhibitory neurons (In-M-cko), or thalamic neurons (Th-H-cko). These models recapitulate core DEE77 features:

"Both Ex-M-cko and In-M-cko mice showed impaired long-term fear memory and were more susceptible to kainic acid-induced seizures." — PMID: 33607654

"Phosphatidylinositol glycan biosynthesis class A protein (PIGA) catalyzes the very first step of GPI anchor biosynthesis. Patients carrying a mutation of the PIGA gene usually suffer from inherited glycosylphosphatidylinositol deficiency (IGD) with intractable epilepsy and intellectual developmental disorder." — PMID: 33607654

In-M-cko mice additionally showed a severe limb-clasping phenotype and Ex-M-cko mice showed hippocampal synapse changes.

Model characteristics / recapitulation. The neuronal GPI-deficiency mouse reproduces seizure susceptibility and cognitive deficits — the neurodevelopmental core of DEE77. Limitations: these use Piga (not its GPI-GnT partner Pigq), are conditional (not the constitutive biallelic human genotype), and do not capture the full multisystem congenital-anomaly spectrum (GI/cardiac/renal). In-vitro human models (patient fibroblasts and iPSC-derived systems) complement animal work: patient fibroblasts provided the definitive rescue experiment (PMID: 32588908).

Model databases / resources: MGI (Pigq, Piga), IMPC, IMSR.

Mechanistic Model / Interpretation

  Biallelic hypomorphic/LoF PIGQ variants (16p13.3)
                │  (autosomal recessive; >=1 residual-activity allele in viable patients)
                v
  Reduced PIGQ subunit  ->  Impaired ER GPI-GnT complex (with PIGA, PIGC, PIGH, PIGP, DPM2, ARV1)
                │            [cytoplasmic face of ER membrane; GO:0005789]
                v
  Failure of 1st committed GPI step: PI + UDP-GlcNAc -> GlcNAc-PI
                │            [GPI anchor biosynthetic process; GO:0006506]
                v
  Global reduction in GPI anchor synthesis
                │
                v
  Deficient surface display of >150 GPI-anchored proteins
  (FLAER-binding anchors, CD16, CD14, CD59, FOLR1, ALPL, adhesion/signaling molecules)
                │
        +-------+--------------------------------+
        v (neuronal branch)                       v (systemic/developmental branch)
  Disrupted neuronal development,           Disrupted organogenesis
  synapse formation, excitability           │
        │                                    v
        v                             GI (volvulus 66%), cardiac (19%),
  Epilepsy (onset 2.5-7 mo, drug-          renal (14%) congenital anomalies
  resistant), hypotonia, GDD/ID,
  progressive cerebral/cerebellar
  atrophy, hypomyelination
        │                                    │
        +------------------+-----------------+
                           v
        DEE77 - early-infantile epileptic encephalopathy
        with multisystem anomalies; >50% premature mortality
                           │
                           v  (partial, non-curative)
        High-dose vitamin B6 (pyridoxine/P5P) -> partial seizure reduction in a subset

Interpretation. DEE77 is best understood as a dosage/residual-activity disorder of the GPI-anchor pathway. The PIGQ lesion is upstream and pathway-initiating; the phenotype is the aggregate downstream consequence of losing many functionally diverse GPI-anchored surface proteins simultaneously. Severity is a graded function of how much GPI biosynthesis survives — explaining the continuum from lethal early-infantile encephalopathy to nonprogressive ataxia. The neurodevelopmental prominence reflects the dependence of neuronal differentiation, synaptogenesis, and excitability control on GPI-anchored molecules, validated by conditional neuronal Piga knockout mice that reproduce seizure susceptibility and memory deficits. The partial pyridoxine responsiveness — shared across IGD — and the butyrate proof-of-concept in PIGM deficiency indicate the pathway is pharmacologically modifiable in principle, motivating mechanism-anchored therapy development.

Evidence Base

Evidence source types: human clinical (24463883, 32588908, 34089469, 38456468, 35080266, 26165085, 17442906, 19732866), in vitro (32588908 fibroblast rescue; 11418246 HEK293 antisense), model organism (33607654), computational (gnomAD constraint, ClinVar and OLS queries performed during the investigation).

Limitations and Knowledge Gaps

1. Ultra-rare evidence base. Fewer than ~20 PIGQ patients are reported; most quantitative frequencies (seizures 83%, DD/ID 90%, etc.) come from the broader IGD cohort (Sidpra 2024), not PIGQ-specific data. PIGQ-specific frequencies, penetrance, and natural history are imprecise.
2. No formal epidemiology. No validated prevalence/incidence; the gnomAD-derived carrier estimate (~1/286) overestimates disease because it ignores embryonic lethality of complete null and the requirement for a hypomorphic allele.
3. No PIGQ-specific animal model. Modeling relies on Piga conditional knockouts; genotype–phenotype fidelity for PIGQ is inferred, not demonstrated.
4. Therapeutics extrapolated. Pyridoxine/P5P and butyrate evidence comes from other GPI genes (PIGA/PIGT/PIGV/PIGM); no PIGQ-specific trial exists. Folinic-acid benefit is mechanistic conjecture.
5. Genotype–phenotype correlation (which variants give the severe vs. mild spectrum) is not systematically established; residual-activity assays per variant are lacking.
6. QoL and long-term outcome are not measured with standardized instruments.

Proposed Follow-up Experiments / Actions

1. Assemble a PIGQ-specific patient registry (via GeneMatcher/consortia) to derive gene-specific phenotype frequencies, survival curves, and genotype–phenotype correlations.
2. Variant-level functional assays. Quantify residual GPI biosynthesis for each reported PIGQ variant (flow cytometry for surface GPI-APs in patient/edited cells) to build a severity-prediction model that would refine prognosis and counseling.
3. Generate a Pigq mouse (or zebrafish) model — conditional/hypomorphic neuronal knockouts — to directly test PIGQ (vs Piga) mechanism and the multisystem anomalies (GI/cardiac/renal).
4. Prospective pyridoxine/P5P trial in PIGQ-DEE77, with EEG/seizure-diary endpoints and GPI-AP flow-cytometry biomarkers, to test whether the subset-benefit seen in other IGDs extends to PIGQ.
5. Test pathway-restoring agents (HDAC inhibitors as in PIGM; substrate/precursor supplementation) in patient iPSC-derived neurons/organoids for PIGQ-specific rescue.
6. Evaluate folinic acid empirically, given FOLR1's GPI dependence, measuring CSF 5-MTHF where feasible.
7. Standardize diagnostic workup: recommend GPI-AP flow cytometry (FLAER/CD16/CD14) as reflex confirmation after ES/WGS identifies biallelic PIGQ variants, plus MRI for prognostic atrophy/tract markers.

Report compiled from 9 confirmed findings and 37 reviewed papers across a 5-iteration autonomous investigation. All mechanistic and clinical claims are anchored to primary literature (PMIDs above) with verified abstract quotations.